Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
US9279008B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9279008-B2 |
| Application number | US-201414181931-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2014 |
| Priority date | Nov 3, 2011 |
| Publication date | Mar 8, 2016 |
| Grant date | Mar 8, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to B7-H4-specific compositions and methods of use thereof.
Opening claim text (preview).
What is claimed is: 1. An isolated polynucleotide encoding a human anti-B7-H4 antibody or a fragment thereof, wherein the antibody or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4. 2. The isolated polynucleotide of claim 1 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 5-8.
involving compounds localised on the membrane of tumour or cancer cells · CPC title
for cancer · CPC title
against B7 molecules, e.g. CD80, CD86 · CPC title
B7 molecules, e.g. CD80, CD86 · CPC title
Fab or Fab' · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.